Funding for this research was provided by:
Institut National Du Cancer (PHRC-K-16-164)
Received: 10 June 2020
Accepted: 28 July 2020
First Online: 5 August 2020
Ethics approval and consent to participate
: The study protocol and its amendments obtained approval from the French Ethics Committee (Comité de Protection des Personnes Ile-de-France VI, reference: 67–17) in December 2017 and from the French National Agency for the Safety of Medicines and Health Products (ANSM) (N°ID - RCB 2017-A02058–45) in October 2017.The study is conducted in accordance with the Helsinki Declaration, the Good Clinical Practice (GCP) guidelines of the International Conference on Harmonisation (ICH–E6, 17/07/96) and local regulatory requirements. Written informed consent will be obtained for each patient by the investigator before any study-related assessment starts.
: Not applicable.
: The authors declare that they have no competing interests.